BNTX | BioNTech SE Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	102.11 - 105.23
52 Week Range	76.53 - 131.49
Beta	1.20
Implied Volatility	45.15%
IV Rank	64.02%
Day's Volume	860,873
Average Volume	1,080,652
Shares Outstanding	240,392,992
Market Cap	25,036,930,117
Sector	Healthcare
Industry	Biotechnology
IPO Date	2019-10-10

Valuation
Profitability
Growth
Health
P/E Ratio	-33.17
Forward P/E Ratio	4.60
EPS	-3.14
1YR Price Target	208.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	6,133
Country	Germany
Website	BNTX

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Comirnaty (COVID-19 vaccine) is its first commercialized product.

BNTX's peers: NVAX, CWBR, DNA, CRSP, OCEA, ENVB, HEPA, ELEV, AVRO, PTCT, KRYS, SRPT, IOVA, MDGL, NVO, VRTX

*Chart delayed

Analyzing fundamentals for BNTX we got that it has average fundamentals where Valuation is considered to be fairly valued, Profitability is unacceptably poor, Growth is exceptionally good and Health is confidently strong. For more detailed analysis please see BNTX Fundamentals page.

Watching at BNTX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on BNTX Technicals page.